Meeting
2022 ASCO Annual Meeting
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
Authors
Diana Lüftner
Charité University Hospital, Berlin, Germany
Diana Lüftner , Cosima Brucker , Thomas Decker , Peter A. Fasching , Thomas Göhler , Christian Jackisch , Jan Janssen , Andreas Koehler , Kerstin Luedtke-Heckenkamp , Marion Van Mackelenbergh , Frederik Marmé , Arnd Nusch , Beate Rautenberg , Toralf Reimer , Marcus Schmidt , Rudolf Weide , Pauline Wimberger , Naiba Nabieva , Christian Roos , Achim Woeckel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
CLEE011ADE03
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1065)
DOI
10.1200/JCO.2022.40.16_suppl.1065
Abstract #
1065
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2019 ASCO Annual Meeting
Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).
First Author: Michelino DeLaurentiis
Poster
2017 ASCO Annual Meeting
Efficacy and safety in elderly patient subsets across studies investigating endocrine monotherapy versus combination therapy in patients with HR+/HER2−advanced breast cancer.
First Author: Rachel A. Freedman